UT Southwestern Harold C. Simmons Comprehensive Cancer Center | Strategic Alliance Partners

Drs Tripathy and McArthur touch on the use of extended adjuvant therapy with neratinib and identify patients who might be suitable for this regimen, including those high-risk patients with residual disease after neoadjuvant therapy.

Virginia G. Kaklamani, MD, DSc, and Melinda L. Telli, MD, review the various adjuvant therapy options available for patients with HER2+ early breast cancer based on stage, risk status, and whether or not they had received neoadjuvant therapy, and then touch on clinical data supporting the use of fixed-dose pertuzumab/trastuzumab (PH) in this setting.

Dr Tripathy provides clinical insight on how he assesses HER2+ eBC patient response to neoadjuvant therapy, discusses the typical prognosis for those who do or do not have residual disease, and touches on how he might approach adjuvant treatment selection for each.

Panelists expand upon the most important clinical factors that inform selection amongst available systemic therapy regimens in the neoadjuvant setting of HER2+ eBC, comment on the potential for treatment de-escalation in lower-risk patients, and discuss exciting treatments on the horizon.

Heather McArthur, MD, and Debu Tripathy, MD, lead a discussion on risk stratification and optimizing treatment for HER2+ early breast cancer (eBC), followed by a review of standard-of-care systemic therapy regimens in the preoperative/neoadjuvant setting.

Closing out her discussion on HER2+ metastatic breast cancer, expert oncologist Virginia Kaklamani, MD, DSc, highlights ongoing unmet needs future directions in care.

Amy Jones, MD, details the socioeconomic challenges with patients coming into the Dallas County clinics and how oncology fellows become equipped to address them.

Closing out their discussion on renal cell carcinoma, key opinion leaders highlight the value of multidisciplinary care and look toward future evolutions in the treatment paradigm.

Expert panelists highlight aspects of a final patient scenario, discussing adjuvant treatment strategies in the setting of renal cell carcinoma at intermediate-high risk for recurrence.

Focused discussion on combination IO-TKI therapy and its role as first-line therapy in patients diagnosed with metastatic renal cell carcinoma.

Moving on to the second patient scenario of renal cell carcinoma, panelists reflect on the treatment pathway for favorable risk metastatic disease.

Before sharing clinical pearls for the treatment of prostate cancer, key opinion leaders reflect on the potential use of immune checkpoint inhibitors in mCRPC.

Expert panelists consider the real-world application of PARP inhibitor data in patients with metastatic castration-resistant prostate cancer.

Key opinion leaders in the field of renal cell carcinoma management discuss the advent of combination immunotherapy in patients with metastatic disease.

Expert perspectives on a patient scenario of intermediate risk metastatic renal cell carcinoma and corresponding management with combination immunotherapy.

Comprehensive insight on the evolving role of PARP inhibitors in metastatic castration-resistant prostate cancer and clinical trials in this setting.

Expert oncologists briefly review the current treatment paradigm of metastatic castration-resistant prostate cancer (mCRPC).

An increased focus on long-term and genomic analyses on established treatments in prostate cancer have revealed new opportunities for patients across disease states.

Closing out their segment on metastatic hormone-sensitive prostate cancer, panelists review other treatment modalities being investigated in clinical trials.

Expert insight on methods to educate patients on available treatment options in the setting of metastatic hormone-sensitive prostate cancer.

Key opinion leaders reflect on data from the TITAN and PEACE-1 clinical trials, respectively, in the setting of metastatic hormone-sensitive prostate cancer.

Shared insight on the ENZAMET and ARCHES clinical trials, which utilized combination enzalutamide strategies in patients with metastatic hormone-sensitive prostate cancer.

Faculty across 4 institutions discuss their participation in a 4-team initiative launched by Stand Up To Cancer® that focuses on expanding access to cancer care and research.

The American Society for Radiation Oncology and European Society for Radiotherapy & Oncology have released the first clinical guideline on the use of definitive local therapy, including radiation and surgery, for the treatment of patients with oligometastatic non–small cell lung cancer.

Experts in prostate cancer consider patient suitability for triplet therapy in the setting of metastatic hormone-sensitive disease.

A focused review of patient and disease factors that inform selection of therapy for patients with metastatic hormone-sensitive prostate cancer.

Centering discussion on metastatic hormone-sensitive prostate cancer (mHSPC), key opinion leaders identify core goals of treatment.

Before shifting focus away from non-metastatic castration-resistant prostate cancer, medical oncologists reflect on means to optimize care and look to future directions in the field.

Experts on non-metastatic castration-resistant prostate cancer share insight on patient monitoring strategies to improve outcomes.

A brief discussion on the role of quality of life in selecting best therapy for patients with non-metastatic castration-resistant prostate cancer.